文献速递甲状腺疾病

维生素D补充对Graves病的影响:DAGMAR试验

Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial.
PubMed 文献 · Thyroid · 2023-06-26

这项多中心、双盲、随机安慰剂对照试验纳入278例首次诊断并接受抗甲状腺药物治疗的Graves病患者,比较维生素D 70 mcg每日一次与安慰剂。维生素D组未能进入并维持缓解的风险为42%,安慰剂组为32%,相对风险1.30(95%CI 0.95-1.78)。结论认为维生素D补充未改善Graves病治疗,不推荐大剂量维生素D补充用于Graves病。

要点

  • 维生素D组未能进入并维持缓解的风险为42%,安慰剂组为32%,相对风险1.30(95%CI 0.95-1.78)。
  • 维生素D补充未改善维生素D状态正常或不足的Graves病患者的治疗。
  • 作者结论认为大剂量维生素D补充不能推荐用于Graves病。

核心结论

  • 维生素D补充未改善维生素D状态正常或不足的Graves病患者的治疗,大剂量维生素D补充不能推荐用于Graves病。

研究设计与样本

  • 多中心、双盲、随机安慰剂对照试验,比较维生素D 70 mcg每日一次(2800 IU)与安慰剂。
  • 干预首先作为抗甲状腺药物的添加治疗,最长24个月,然后在停用抗甲状腺药物后继续12个月。
  • 纳入期为2015年至2017年,研究于2020年12月完成。
  • 纳入对象为首次诊断并接受抗甲状腺药物治疗的成人Graves病患者,排除妊娠和糖皮质激素治疗者。
  • 共纳入278例患者,4例撤回知情同意。

主要发现

  • 入组时参与者年龄44±14岁,79%为女性。
  • 未能进入并维持缓解的风险在维生素D组为42%(95%CI 33-50%),在安慰剂组为32%(95%CI 24-40%)。
  • 相对风险为1.30(95%CI 0.95-1.78)。
  • 未发现不良反应。

关键数值与推荐

  • 主要终点为未能进入并维持缓解,定义为停用抗甲状腺药物后12个月内甲状腺功能亢进复发、24个月内无法停用抗甲状腺药物、或接受放射性碘治疗或甲状腺切除术。

临床怎么用

  • 作者结论认为大剂量维生素D补充不能推荐用于Graves病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Treatment options in Graves' disease (GD) are limited and do not target the underlying autoimmunity, and relapse rates following a course of antithyroid drug (ATD) reach 50%. Previous research has shown promising results for a role of vitamin D in GD. We aimed to investigate whether vitamin D reduces failure to enter and sustain remission in patients with GD treated with ATD. Design: A multicenter, double-blinded, randomized placebo-controlled trial comparing vitamin D 70 mcg once daily (2800 IU) or placebo. The intervention was given first as add-on to ATD treatment, maximally 24 months, and then for 12 months after ATD cessation. Inclusion period was from 2015 to 2017 and study completion by December 2020. Patients included were adults with a first-time diagnosis of GD treated with ATD. Exclusion criteria included pregnancy and glucocorticoid treatment. The primary endpoint was failure to enter and sustain remission defined as relapse of hyperthyroidism within 12 months after ATD cessation, inability to stop ATD within 24 months, or radioiodine treatment or thyroidectomy. Two hundred seventy-eight patients were included in the study, and 4 patients withdrew consent. No adverse effects were found. Results: Participants were aged 44 ± 14 years at enrollment and 79% were female. The risk of failure to enter and sustain remission was 42% [95% confidence interval (CI) 33-50%] in the vitamin D group and 32% [CI 24-40%] in the placebo group corresponding to a relative risk of 1.30 [CI 0.95-1.78]. Conclusions: Vitamin D supplementation did not improve the treatment of GD in patients with normal or insufficient vitamin D status. Thus, supplementation with high-dose vitamin D cannot be recommended for GD. Study registration: ClinicalTrials.gov NCT02384668.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Grove-Laugesen D, Ebbehoj E, Watt T, et al. Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial. Thyroid. 2023. PMID: 37218433. doi:10.1089/thy.2023.0111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。